Karsenty Gilles, Corcos Jacques, Schurch Brigitte
Service d'Urologie, Hôpital Salvator, Marseille, France.
Prog Urol. 2006 Jun;16(3):263-74.
Botulinum toxins (BT) are one of the most powerful poisons in nature. They are responsible for human botulism and constitute a potential chemical weapon, but can also be used as a therapeutic agent. Sphincter, bladder and prostatic injections have been described in urological indications as varied as detrusor-sphincter dyssynergia and neurogenic detrusor hyperactivity, idiopathic overactive bladder symptoms, interstitial cystitis, obstructive voiding disorders related to benign prostatic hyperplasia or chronic prostatitis, and recurrent urethral stricture. This review of the literature presents the results and level of evicence in support of the use of BT in urological indications. Detrusor injections of BT-A constitute an alternative conservative treatment that is effective in the short term (6-12 months) after failure of anticholinergic agents to treat neurogenic detrusor hyperactivity (level 1b). Sphincter injections are effective in the short-term treatment of neurogenic detrusor-sphincter dyssynergia (level 1c). The efficacy observed during preliminary clinical trials of detrusor injections of BT-A for idiopathic overactive bladder symptoms or interstitial cystitis (level 4) and prostatic injections for obstruction related to BPH (level 1c) justifies the major interest raised by this new therapeutic approach. However, these preliminary results must be confirmed by comparative studies on a sufficient number of patients with long-term follow-up before considering the use of this technique in routine clinical practice.
肉毒杆菌毒素(BT)是自然界中最强大的毒物之一。它们可导致人类肉毒中毒,是一种潜在的化学武器,但也可作为治疗剂使用。在泌尿外科适应症中,已描述了括约肌、膀胱和前列腺注射,这些适应症包括逼尿肌-括约肌协同失调和神经源性逼尿肌活动亢进、特发性膀胱过度活动症症状、间质性膀胱炎、与良性前列腺增生或慢性前列腺炎相关的梗阻性排尿障碍以及复发性尿道狭窄。本文献综述展示了支持在泌尿外科适应症中使用BT的结果和证据水平。在抗胆碱能药物治疗神经源性逼尿肌活动亢进失败后的短期内(6 - 12个月),注射BT - A到逼尿肌是一种有效的替代保守治疗方法(证据水平1b)。注射到括约肌对神经源性逼尿肌-括约肌协同失调有短期治疗效果(证据水平1c)。在针对特发性膀胱过度活动症症状或间质性膀胱炎进行的BT - A逼尿肌注射(证据水平4)以及针对与良性前列腺增生相关梗阻进行的前列腺注射(证据水平1c)的初步临床试验中观察到的疗效,证明了这种新治疗方法引起的广泛关注是合理的。然而,在考虑将该技术应用于常规临床实践之前,这些初步结果必须通过对足够数量患者进行长期随访的比较研究来证实。